Clinical significance of integrin β6 as a tumor recurrence factor in follicular thyroid carcinoma.
BACKGROUND
Overexpression of integrin β6 plays an important role in a variety of malignant tumor invasion and metastasis.


METHODS
The expression levels of integrin β6, matrix metalloproteinase (MMP)-2 and MMP-9 were analyzed by immunohistochemistry with human follicular thyroid carcinomas. Then we investigated their correlation with clinical outcomes parameters, relationship, and the survival time.


RESULTS
The integrin β6 staining was expressed in cellular membrane and cytoplasm of follicular thyroid carcinoma cells. The MMP-2 and MMP-9 expressions were mainly found in cellular cytoplasm. In correlation with the clinical outcome parameters of 60 patients, there were significant statistical differences of integrin β6, MMP-2, and MMP-9 expression levels in different size of tumor. Integrin β6 and MMP-9 expressions have significant statistical differences in T classifications. MMP-2 and MMP-9 expressions have significant statistical differences in different M classification. Other clinical outcome parameters had no significant statistical differences.


CONCLUSIONS
Integrin β6 expression correlated significantly with MMP-9 expression, and may be a valuable recurrence indicator for follicular thyroid carcinomas.
Department of Hepatobiliary Surgery, Qilu Hospital, Shandong University, Shandong, People's Republic of China.|Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Public Health, Shandong, People's Republic of China.
Zhuo-nan
ZN
Zhuang
Department of Clinical Laboratory, Rizhao People's Hospital, People's Republic of China.
Zhen-jie
ZJ
Xu
Department of Radiology, Jinan Central Hospital Affiliated to Shandong University, Shandong, People's Republic of China.
Qian
Q
Zhou
Department of Surgery, Chang-Hai Hospital, The Second Military Medical University, Shanghai, People's Republic of China.
Xiao-zhou
XZ
Xu
Department of Lymphoma, MD Anderson Cancer Center, University of Texas, Houston, Texas.
Jessie
J
Tian
Department of Hepatobiliary Surgery, Qilu Hospital, Shandong University, Shandong, People's Republic of China.|Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Public Health, Shandong, People's Republic of China.
Yan-feng
YF
Liu
Department of Hepatobiliary Surgery, Qilu Hospital, Shandong University, Shandong, People's Republic of China.
Sen
S
Guo
Department of Hepatobiliary Surgery, Qilu Hospital, Shandong University, Shandong, People's Republic of China.
Jia-yong
JY
Wang
Department of Hepatobiliary Surgery, Qilu Hospital, Shandong University, Shandong, People's Republic of China.
Ke-sen
KS
Xu
D018263:Adenocarcinoma, Follicular / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D039641:Integrin beta Chains / Q000378:metabolism*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000378:metabolism*; D011379:Prognosis; D055815:Young Adult
D014408:Biomarkers, Tumor; D039641:Integrin beta Chains; C072170:integrin beta6; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9
MMP-9; follicular thyroid carcinoma; integrin β6; matrix metalloproteinase (MMP)-2; recurrence